Thiazolidinedione‐induced skeletal fragility – mechanisms and implications
- 24 February 2009
- journal article
- review article
- Published by Wiley in Diabetes, Obesity and Metabolism
- Vol. 11 (4), 275-284
- https://doi.org/10.1111/j.1463-1326.2008.00931.x
Abstract
Recent evidence suggests that the risk of several types of fracture is increased in type 2 diabetes mellitus (T2DM). Thiazolidinediones (TZDs) are now widely used in the management of T2DM, and their use may increase in other diseases characterized by insulin resistance. The PPAR‐γ, the molecular target of the TZDs currently in clinical use, is expressed in skeletal tissue. Evidence from preclinical studies has demonstrated that activation of PPAR‐γ (i) inhibits bone formation by diverting mesenchymal stem cells from the osteogenic to the adipocytic lineage and (ii) may increase bone resorption by stimulating the development of osteoclasts. There is also potential for indirect adverse skeletal effects of PPAR‐γ activation by modulation of circulating levels of hormones and cytokines known to influence bone metabolism. Recent studies in humans have demonstrated that TZDs decrease markers of bone formation decrease bone mass, and increase fracture rates, at least in women. The implication of these findings is that fracture risk should be considered in patients with T2DM for whom TZD therapy is being considered, and appropriate therapy instigated to prevent fractures in individuals ascertained to be at high risk.This publication has 77 references indexed in Scilit:
- Effects of pioglitazone on major adverse cardiovascular events in high-risk patients with type 2 diabetes: Results from PROspective pioglitAzone Clinical Trial In macro Vascular Events (PROactive 10)American Heart Journal, 2008
- Rosiglitazone Induces Decreases in Bone Mass and Strength that Are Reminiscent of Aged BoneEndocrinology, 2007
- Activation of Peroxisome Proliferator-Activated Receptor γ (PPARγ) by Rosiglitazone Suppresses Components of the Insulin-Like Growth Factor Regulatory System in Vitro and in VivoEndocrinology, 2007
- Thiazolidinedione Use and Bone Loss in Older Diabetic AdultsJournal of Clinical Endocrinology & Metabolism, 2006
- Netoglitazone is a PPAR-gamma ligand with selective effects on bone and fatBone, 2006
- Nontraumatic Fracture Risk With Diabetes Mellitus and Impaired Fasting Glucose in Older White and Black AdultsArchives of Internal Medicine, 2005
- Distinct effects of PPARγ insufficiency on bone marrow cells, osteoblasts, and osteoclastic cellsJournal of Bone and Mineral Metabolism, 2005
- Adiponectin increases bone mass by suppressing osteoclast and activating osteoblastBiochemical and Biophysical Research Communications, 2005
- Leptin Production in Adipocytes from Morbidly Obese Subjects: Stimulation by Dexamethasone, Inhibition with Troglitazone, and Influence of GenderJournal of Clinical Endocrinology & Metabolism, 2000
- Activation of Peroxisome Proliferator-activated Receptor-γ Pathway Inhibits Osteoclast DifferentiationOnline Journal of Public Health Informatics, 2000